CECILIA MATHEWS: Open Payments
NPI 1912903576 · MARIANNA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,669 in 67 payments from 12 companies in 2025. Trend: 2023 $1,115 · 2024 $825 · 2025 $1,669
Food & beverage: $1,669
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $449 |
| Supernus Pharmaceuticals, Inc. | 24 | $188 |
| Neurocrine BioSciences, Inc. | 3 | $186 |
| Vanda Pharmaceuticals Inc. | 7 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $155 |
| Axsome Therapeutics, Inc. | 3 | $152 |
| MDD US Operations, LLC | 1 | $118 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
| Alkermes, Inc. | 2 | $50 |
Products named: VRAYLAR, Qelbree, INGREZZA, FANAPT, CAPLYTA, Auvelity, REXULTI, COBENFY.
Industry payments across FL — which companies pay providers there.
